ES2616912T3 - Vacuna contra la diarrea debida a E. coli enterotoxigénica (ETEC) y el cólera - Google Patents

Vacuna contra la diarrea debida a E. coli enterotoxigénica (ETEC) y el cólera Download PDF

Info

Publication number
ES2616912T3
ES2616912T3 ES10817520.9T ES10817520T ES2616912T3 ES 2616912 T3 ES2616912 T3 ES 2616912T3 ES 10817520 T ES10817520 T ES 10817520T ES 2616912 T3 ES2616912 T3 ES 2616912T3
Authority
ES
Spain
Prior art keywords
wbet
ogawa
inaba
etec
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10817520.9T
Other languages
English (en)
Spanish (es)
Inventor
Jan Holmgren
Michael Lebens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd
Original Assignee
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSD Wellcome Trust Hilleman Laboratories Pvt Ltd filed Critical MSD Wellcome Trust Hilleman Laboratories Pvt Ltd
Application granted granted Critical
Publication of ES2616912T3 publication Critical patent/ES2616912T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
ES10817520.9T 2009-09-16 2010-09-16 Vacuna contra la diarrea debida a E. coli enterotoxigénica (ETEC) y el cólera Active ES2616912T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27235109P 2009-09-16 2009-09-16
US272351P 2009-09-16
PCT/SE2010/050996 WO2011034495A1 (en) 2009-09-16 2010-09-16 Vaccine against cholera and enterotoxigenic e. coli (etec) diarrhea

Publications (1)

Publication Number Publication Date
ES2616912T3 true ES2616912T3 (es) 2017-06-14

Family

ID=43758898

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10817520.9T Active ES2616912T3 (es) 2009-09-16 2010-09-16 Vacuna contra la diarrea debida a E. coli enterotoxigénica (ETEC) y el cólera

Country Status (15)

Country Link
US (1) US9511133B2 (enExample)
EP (1) EP2477649B1 (enExample)
JP (2) JP2013505017A (enExample)
KR (1) KR101722802B1 (enExample)
CN (1) CN102630166B (enExample)
AU (1) AU2010296065B2 (enExample)
CA (1) CA2774335C (enExample)
DK (1) DK2477649T3 (enExample)
ES (1) ES2616912T3 (enExample)
HU (1) HUE031957T2 (enExample)
IN (1) IN2012DN02860A (enExample)
PL (1) PL2477649T3 (enExample)
PT (1) PT2477649T (enExample)
WO (1) WO2011034495A1 (enExample)
ZA (1) ZA201202710B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CN102824632A (zh) * 2012-09-12 2012-12-19 北京民海生物科技有限公司 霍乱弧菌o1群多糖结合疫苗、其制备方法及应用
RU2535122C1 (ru) * 2013-11-06 2014-12-10 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения холерогена-анатоксина
RU2563620C2 (ru) * 2014-08-05 2015-09-20 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения таблетированной формы холерной бивалентной химической вакцины
US10987415B2 (en) * 2015-12-14 2021-04-27 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Process for production of purified recombinant cholera toxin B (rCTB) and formulation thereon
JP6820565B2 (ja) * 2016-04-27 2021-01-27 国立大学法人大阪大学 病原性細菌の定着を阻害するペプチド及びそれを含む定着阻害剤
WO2019115001A1 (en) 2017-12-15 2019-06-20 Valneva Sweden Ab Methods and compositions for preventing and/or treating cancer
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera
JP2022545265A (ja) * 2019-08-20 2022-10-26 ニューリタス リミテッド 筋萎縮を治療するためのペプチド
WO2021105061A1 (en) 2019-11-25 2021-06-03 Gotovax Ab Whole cell vaccines and methods of production thereof
WO2022074061A1 (en) 2020-10-07 2022-04-14 Valneva Sweden Ab Cholera vaccine formulation
WO2022117823A1 (en) 2020-12-04 2022-06-09 Valneva Se Methods and compositions for preventing and/or treating autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882653A (en) 1983-03-04 1999-03-16 The University Of Maryland System Vibrio cholerae 01 (CVD111) and non-01 (CVD112 and CVD112RM) serogroup vaccine strains, methods of making same and products thereof
US5330753A (en) * 1987-04-29 1994-07-19 President And Fellows Of Harvard College Cholera vaccines
ATE242319T1 (de) * 1992-07-06 2003-06-15 Harvard College Deletionsmutanten als impfstoffe gegen cholera
US6203799B1 (en) 1993-07-01 2001-03-20 Presidents And Fellows Of Harvard College Vibrio cholerae mutants which are soft-agar penetration defective and lack a functional CtxA subunit
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
WO2000067784A1 (en) 1999-05-10 2000-11-16 University Of Maryland, Baltimore Bacteriophage isolated from bacterial genomes and extrachromosomal elements and methods of use thereof
US7270961B2 (en) 2002-04-16 2007-09-18 Hui Sunny Chang In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes
US20060171966A1 (en) 2002-08-30 2006-08-03 Centre For Health And Population Research Variants of vibrio cholerae 01 biotype e1 tor with attributes of classical biotype
CU23334A1 (es) * 2003-03-20 2008-12-24 Inst Finlay Vacuna de vibrio cholerae inactivada en tabletas
US20060099229A1 (en) 2004-11-05 2006-05-11 Universiti Sains Malaysia Vibrio cholerae strains VCUSM1 and VCUSM4, method of producing same, and vaccine derivatives thereof
EP1543836A1 (en) * 2003-12-17 2005-06-22 Berna Biotech AG Recombinant Vibrio cholerae strain and vaccine comprising said strain
WO2009049013A2 (en) * 2007-10-09 2009-04-16 Tufts University Cholera vaccines

Also Published As

Publication number Publication date
US9511133B2 (en) 2016-12-06
ZA201202710B (en) 2015-12-23
CA2774335C (en) 2016-10-18
JP2013505017A (ja) 2013-02-14
EP2477649A1 (en) 2012-07-25
CN102630166B (zh) 2015-08-05
IN2012DN02860A (enExample) 2015-06-19
KR20120081600A (ko) 2012-07-19
PT2477649T (pt) 2017-03-01
CN102630166A (zh) 2012-08-08
EP2477649B1 (en) 2016-11-23
PL2477649T3 (pl) 2017-06-30
DK2477649T3 (en) 2017-03-06
JP2016074695A (ja) 2016-05-12
EP2477649A4 (en) 2013-01-30
KR101722802B1 (ko) 2017-04-03
US20120276146A1 (en) 2012-11-01
CA2774335A1 (en) 2011-03-24
JP6178384B2 (ja) 2017-08-09
HUE031957T2 (en) 2017-09-28
AU2010296065B2 (en) 2015-05-21
WO2011034495A1 (en) 2011-03-24
AU2010296065A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
JP6178384B2 (ja) コレラおよび毒素原性大腸菌（ｅｔｅｃ）下痢に対するワクチン
CN101969990B (zh) 增强针对艾美球虫属的免疫反应的组合物和方法
KR102515835B1 (ko) UspA2 단백질 구축물 및 그의 용도
US20130287810A1 (en) Vaccine compositions and uses thereof
US11406696B2 (en) P aeruginosa PcrV-linked antigen vaccines
Karlsson et al. Development of stable Vibrio cholerae O1 Hikojima type vaccine strains co–expressing the Inaba and Ogawa Lipopolysaccharide Antigens
JP4583607B2 (ja) 感染症の治療のための弱毒化微生物
JPH08503602A (ja) 弱毒化細菌における組換え融合タンパク質の発現
JP2010017190A (ja) アジュバントとしてのコレラホロトキシンの突然変異形
AU2007338383A1 (en) RSV F-protein and use thereof
JP2011502165A (ja) 鞭毛細菌に対する免疫応答を強化する組成物および方法
JPH04502402A (ja) 組み換えフラジエリンのワクチン
KR102071743B1 (ko) 신규의 약독화된 시겔라 생백신
US9061002B2 (en) Use of flagellins from the genus Marinobacter as vaccination adjuvants
CN101880647B (zh) 重组猪霍乱沙门氏菌及二价基因工程疫苗与应用
WO2022034221A1 (en) Salmonella vaccine for the treatment of coronavirus
Wang et al. Neutralizing-antibody-mediated protection of chickens against infectious bursal disease via one-time vaccination with inactivated recombinant Lactococcus lactis expressing a fusion protein constructed from the RCK protein of Salmonella enterica and VP2 of infectious bursal disease virus
CA2846354A1 (en) Vaccine for protection against etec-induced diarrhea comprising dmlt
Kovacs-Nolan et al. Tandem copies of a human rotavirus VP8 epitope can induce specific neutralizing antibodies in BALB/c mice
Wang et al. Two oral HBx vaccines delivered by live attenuated Salmonella: both eliciting effective anti-tumor immunity
CN1653084A (zh) 酶活性减少的非典型流感嗜血杆菌的p4蛋白突变体
JP2022511511A (ja) 百日咳ブースターワクチン
US20240139304A1 (en) P aeruginosa pcrv-linked antigen vaccines
KR20200046059A (ko) 그룹 a 스트렙토코쿠스에 대한 면역원성 펩티드
Neugebauer et al. Development of a vaccine marker technology: Display of B cell epitopes on the surface of recombinant polyomavirus‐like pentamers and capsoids induces peptide‐specific antibodies in piglets after vaccination